

# VU Research Portal

## I-125 seed implants for prostate brachytherapy

Steggerda, M.J.

2010

### **document version**

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

### **citation for published version (APA)**

Steggerda, M. J. (2010). *I-125 seed implants for prostate brachytherapy: Physical characteristics and relations with post-implant quality of life*. [PhD-Thesis – Research external, graduation internal, Vrije Universiteit Amsterdam].

### **General rights**

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

### **Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

### **E-mail address:**

[vuresearchportal.ub@vu.nl](mailto:vuresearchportal.ub@vu.nl)

# Contents

|   |           |
|---|-----------|
| <b>1. General introduction</b>  | <b>9</b>  |
| 1.1 Treatment of prostate cancer  | 10        |
| 1.1.1 Incidence rates and considerations for treatment  | 10        |
| 1.1.2 Radical treatment   | 11        |
| 1.1.3 Androgen deprivation therapy (ADT)  | 11        |
| 1.2 Quality of life (QOL) after treatment   | 12        |
| 1.3 Brachytherapy: indications and PSA failure  | 13        |
| 1.3.1 Indications   | 13        |
| 1.3.2 PSA failure   | 13        |
| 1.4 Brachytherapy techniques  | 14        |
| 1.5 Evaluation of brachytherapy seed implants   | 16        |
| 1.6 Objective of this thesis  | 17        |
| References  | 19        |
| <b>2. The applicability of simultaneous TRUS-CT imaging for the evaluation of prostate seed implants</b>              | <b>23</b> |
| Abstract  | 24        |
| 2.1 Introduction  | 25        |
| 2.2 Materials and methods   | 26        |
| 2.2.1 Scanning procedure and implant characteristics  | 26        |
| 2.2.2 Image fusion  | 26        |
| 2.2.3 Accuracy of registration procedure  | 31        |
| 2.2.4 Dose distribution evaluation  | 32        |
| 2.3 Results   | 33        |
| 2.3.1 Registration success rate   | 33        |
| 2.3.2 Accuracy of registration procedure  | 35        |
| 2.3.3 Image fusion and dose distribution evaluation   | 37        |
| 2.4 Discussion  | 40        |
| 2.5 Conclusion  | 43        |
| References  | 45        |
| <b>3. The influence of geometrical changes on the dose distribution after I-125 seed implantation of the prostate</b> | <b>47</b> |
| Abstract  | 48        |
| 3.1 Introduction  | 49        |
| 3.2 Materials and methods   | 50        |
| 3.2.1 Imaging of the urethra  | 50        |
| 3.2.2 Determination of dose distribution  | 51        |
| 3.2.3 Implant volume versus prostate volume   | 52        |
| 3.3 Results   | 52        |
| 3.3.1 DVHs based on scans at different post-implant time intervals  | 52        |
| 3.3.2 Integration of dose rates   | 53        |

|           |   |           |
|-----------|---|-----------|
| 3.3.3     | DVHs based on a single scan compared to DVHs taking into account geometrical changes  | 54        |
| 3.3.4     | Time dependence of dose-volume parameters   | 55        |
| 3.3.5     | Physical characteristics of changes in prostate and implant geometry  | 56        |
| 3.4       | Discussion  | 57        |
| 3.4.1     | Influence of post-implant scan date on dose-volume parameters of the prostate   | 57        |
| 3.4.2     | Dose to urinary system  | 58        |
| 3.4.3     | Expected inaccuracies in geometry corrected dose-volume parameters  | 59        |
| 3.4.4     | Physical aspects of geometrical changes   | 59        |
| 3.5       | Conclusions   | 61        |
|           | References  | 62        |
| <b>4.</b> | <b>Predicting urinary morbidity after brachytherapy of localized prostate cancer</b>  | <b>65</b> |
|           | Abstract  | 66        |
| 4.1       | Introduction  | 67        |
| 4.2       | Irritative and obstructive symptoms   | 67        |
| 4.3       | Acute urinary retention   | 72        |
| 4.4       | Androgen deprivation therapy  | 74        |
| 4.5       | Transurethral resection and incontinence  | 74        |
| 4.6       | Radionuclide  | 75        |
| 4.7       | Use of $\alpha$ -blockers   | 76        |
| 4.8       | Long-term urinary quality of life   | 77        |
| 4.9       | Conclusions   | 77        |
|           | References  | 79        |
| <b>5.</b> | <b>An analysis of the relation between physical characteristics of prostate I-125 seed implants and lower urinary tract symptoms: bladder hotspot dose and prostate size are significant predictors</b> | <b>83</b> |
|           | Abstract  | 84        |
| 5.1       | Introduction  | 85        |
| 5.2       | Materials and methods   | 86        |
| 5.2.1     | Patients and implants   | 86        |
| 5.2.2     | Urinary symptom scores  | 86        |
| 5.2.3     | Early urinary categories  | 87        |
| 5.2.4     | Imaging and dosimetry   | 87        |
| 5.2.5     | Statistics  | 88        |
| 5.3       | Results   | 89        |
| 5.3.1     | IPSS endpoints  | 89        |
| 5.3.2     | Urinary retention and early symptoms  | 92        |
| 5.4       | Discussion  | 94        |
| 5.4.1     | Bladder hotspot dose and urinary morbidity  | 94        |

|           |   |            |
|-----------|---|------------|
| 5.4.2     | Predicting urinary morbidity  | 95         |
| 5.4.3     | Irritative and obstructive complaints   | 96         |
| 5.4.4     | Implications for clinical practice  | 97         |
| 5.5       | Conclusions.  | 97         |
|           | References  | 99         |
| <b>6.</b> | <b>Minimizing the number of implantation needles for prostate I-125 brachytherapy; an investigation of possibilities and implications</b> | <b>101</b> |
|           | Abstract  | 102        |
| 6.1       | Introduction  | 103        |
| 6.2       | Methods and materials   | 104        |
| 6.2.1     | Inter-seed spacing  | 104        |
| 6.2.2     | Implantation planning and objectives for optimization   | 104        |
| 6.2.3     | Sensitivity for random seed placement errors  | 108        |
| 6.2.4     | Comparison of clinical cases  | 108        |
| 6.3       | Results   | 109        |
| 6.3.1     | Influence of needle reduction on the dose distribution  | 109        |
| 6.3.2     | Sensitivity for random seed placement errors  | 110        |
| 6.3.3     | Comparison of clinical cases  | 113        |
| 6.4       | Discussion  | 114        |
| 6.4.1     | Outcomes planning study   | 114        |
| 6.4.2     | Geometrical uncertainties   | 115        |
| 6.4.3     | Dose distribution of clinical cases   | 116        |
| 6.4.4     | Facts from literature   | 117        |
| 6.5       | Conclusions   | 118        |
|           | References  | 120        |
| <b>7.</b> | <b>General discussion</b>   | <b>123</b> |
| 7.1       | Multi-modality imaging of the prostate  | 124        |
| 7.2       | Post-implant seed kinetics and anatomy changes  | 126        |
| 7.3       | Relation between physical properties of seed implants and side effects  | 128        |
| 7.4       | The potentials and future developments of prostate brachytherapy  | 130        |
| 7.4.1     | BT compared with advanced EBRT techniques   | 130        |
| 7.4.2     | Implantation techniques   | 134        |
| 7.4.3     | Dose differentiation within the prostate  | 135        |
| 7.4.4     | Future directions   | 136        |
|           | References  | 137        |
|           | <b>Summary</b>  | <b>141</b> |
|           | <b>Samenvatting</b>   | <b>147</b> |
|           | <b>List of publications</b>   | <b>154</b> |

**Dankwoord**  
**Over de auteur**

**156**  
**160**